FLASCO
- NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and other Cancer Types Based on Emerging Evidence March 18, 2024The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for any area of medicine and are used by cancer care providers worldwide to stay up to...
- New Study Shows Medical Debt Associated With Worse Health Status, More Premature Deaths, and Higher Mortality Rates at the County Level in the U.S. March 18, 2024New findings led by American Cancer Society (ACS) researchers shows medical debt was associated with more days of poor physical and mental health, more years of life lost, and higher mortality rates for all-cause and leading causes of death at the county level in the United States. The study is published today in the Journal...
- FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma March 7, 2024On March 7, 2024, the Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
- FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma March 7, 2024On March 6, 2024, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).
- FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia March 6, 2024On March 6, 2024, the Food and Drug Administration approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
- NIH to Address Dwindling Clinical Trial Patient Enrollment With Centralized Staffing Support March 6, 2024A new initiative by the National Cancer Institute (NCI), part of the National Institutes of Health, aims to tackle the steep decline in participation in NCI-funded cancer clinical trials that is due in part to clinical trials staffing shortages that were exacerbated by the COVID-19 pandemic. These shortfalls have hampered clinical trials activities across the...
- Advocating for Equitable Cancer Care: A Call to Establish Comprehensive Survivorship Programming and Enhance Genetic Testing Discussions March 6, 2024Two new measurements have been added to the Health Equity Report Card (HERC)—a tool for improving the quality and equity of cancer care. The new measures were put forth by a multi-disciplinary working group of experts in community oncology and agreed to by the original Elevating Cancer Equity working group members who drafted the original...
- President’s Cancer Panel Issues Recommendations to Advance National Cancer Plan March 6, 2024Yesterday the President’s Cancer Panel issued a report on the National Cancer Plan, which aims to reduce cancer mortality by at least 50% over 25 years and enhance the well-being of individuals and families affected by cancer. The report is derived from the panel’s September 2023 stakeholder meeting, in which ASCO and other organizations participated....
- New Policy Statement Addresses Social, Economic, and Environmental Factors Influencing Cancer Care, Outcomes March 6, 2024ASCO’s new policy statement highlights the need for formalized efforts to address health- related social needs and outlines ways to address social determinants of health (SDOH) in cancer care. Social determinants are defined as conditions in which people are born, grow, live, work, and age, which may include underlying social, economic, and environmental conditions. The...
- American Cancer Society Launches Training and Credentialing Program to Standardize and Support High-Quality Oncology Patient Navigation March 6, 2024The American Cancer Society announced the launch of the American Cancer Society Leadership in Oncology Navigation (ACS LIONTM) program, a national training and credentialing program that is working with oncology organizations to standardize high-quality, expert patient navigation for persons with cancer and their caregivers. Oncology navigation professionals work with patients within clinics and community-based settings,...